Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 2
1995 1
1996 1
1999 1
2010 1
2013 1
2020 1
2021 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.
Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P, Røder MA, Brasso K, Gouttefangeas C. Schuhmacher J, et al. Among authors: balchen t. J Immunother Cancer. 2020 Nov;8(2):e001157. doi: 10.1136/jitc-2020-001157. J Immunother Cancer. 2020. PMID: 33184050 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.
Backer V, Sjöbring U, Sonne J, Weiss A, Hostrup M, Johansen HK, Becker V, Sonne DP, Balchen T, Jellingsø M, Sommer MOA. Backer V, et al. Among authors: balchen t. Lancet Reg Health Eur. 2021 May;4:100084. doi: 10.1016/j.lanepe.2021.100084. Epub 2021 Apr 6. Lancet Reg Health Eur. 2021. PMID: 33842908 Free PMC article.
Dose safety and pharmacodynamics of subcutaneous bupivacaine in a novel extended-release microparticle formulation: A phase 1, dose-ascending study in male volunteers.
Jensen EK, Bøgevig S, Balchen T, Springborg AH, Royal MA, Storgaard IK, Lund TM, Møller K, Werner MU. Jensen EK, et al. Among authors: balchen t. Basic Clin Pharmacol Toxicol. 2024 May;134(5):657-675. doi: 10.1111/bcpt.13998. Epub 2024 Mar 14. Basic Clin Pharmacol Toxicol. 2024. PMID: 38482995 Clinical Trial.
Safety, Tolerability, and Pharmacodynamics of the ADAMTS-5 Nanobody M6495: Two Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies in Healthy Subjects and Patients With Osteoarthritis.
Bihlet AR, Balchen T, Goteti K, Sonne J, Ladel C, Karsdal MA, Ona V, Moreau F, Waterhouse R, Bay-Jensen AC, Guehring H. Bihlet AR, et al. Among authors: balchen t. ACR Open Rheumatol. 2024 Apr;6(4):205-213. doi: 10.1002/acr2.11610. Epub 2024 Feb 4. ACR Open Rheumatol. 2024. PMID: 38311369 Free PMC article.
Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
Verhamme P, Pakola S, Jensen TJ, Berggren K, Sonesson E, Saint-Remy JM, Balchen T, Belmans A, Cahillane G, Stassen JM, Peerlinck K, Glazer S, Jacquemin M. Verhamme P, et al. Among authors: balchen t. Clin Ther. 2010 Jun;32(6):1205-20. doi: 10.1016/j.clinthera.2010.06.012. Clin Ther. 2010. PMID: 20637972 Clinical Trial.
14 results